Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
Stopped Study terminated to end of funding.
Conditions
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma
Interventions
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Pembrolizumab
- BIOLOGICAL: Rituximab
- BIOLOGICAL: Obinutuzumab
Sponsor
University of Washington
Collaborators